Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?-Reference-Cited by-同舟云学术

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Published:2015-02-12 Issue:3 Volume:71 Page:341-355
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Birmingham Bruce K.,Bujac Sarah R.,Elsby Robert,Azumaya Connie T.,Wei Cheryl,Chen Yusong,Mosqueda-Garcia Rogelio,Ambrose Helen J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-014-1801-z.pdf

Reference26 articles.

1. Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, Ikeda Y, Nii M (2004) Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11:152–158

2. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341

3. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group (2007) Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 99:1538–1543

4. Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C (2007) A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 23:3055–3068

5. Warwick MJ, Dane AL, Raza A, Schneck DW (2000) Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 151:39 (Abstract)

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review;Diabetology;2024-09-03

2. Redefining Statin Dosage Post‐Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach;The Journal of Clinical Pharmacology;2024-08-05

3. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population;Current Vascular Pharmacology;2024-05

4. The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians;Hong Kong Medical Journal;2024-04-12

5. Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP;Clinical Pharmacology & Therapeutics;2024-03-17